| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
88-216 |
DRI_Background |
denotes |
Prevention of nausea and vomiting is the main goal of antiemetic treatment in cancer patients scheduled to receive chemotherapy. |
| T2 |
217-384 |
DRI_Approach |
denotes |
To prevent acute emesis, antiemetics should be administered just before chemotherapy and patients should be protected for up to 24 hours after chemotherapy initiation. |
| T3 |
385-507 |
DRI_Background |
denotes |
The emetogenic potential of chemotherapeutic agents guides clinicians towards the most appropriate antiemetic prophylaxis. |
| T4 |
508-693 |
DRI_Background |
denotes |
Current guidelines recommend the use of 5-HT(3) receptor antagonist (RA) either alone or in combination with dexamethasone and/or a neurokinin-1 RA both in the acute and delayed phases. |
| T5 |
694-820 |
DRI_Background |
denotes |
The second-generation 5-HT(3)RA palonosetron exhibits a longer half-life and a higher binding affinity than older antagonists. |
| T6 |
821-1095 |
DRI_Background |
denotes |
Palonosetron has been approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients scheduled to receive either moderately (MEC) or highly emetogenic chemotherapy (HEC) and for the prevention of delayed CINV in patients receiving MEC. |
